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The potential anxiolytic and anti-depressive activity of CMP1 was studied in the elevated plus-maze test and in the forced 
swimming test. Furthermore, CMP1 sedative activity was evaluated in pentobarbital treated animals; the effect of CMP1 on 
spontaneous motor activity (total locomotion) was also evaluated. Our data show that CMP1, at doses that did not affect 
locomotion, was able to induce anxiolytic and sedative, but not anti-depressive effects. In conclusion, our results represent first 
evidence for an anxiolytic activity of this diterpenoid from Salvia cinnabarina.  
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In a screening programme on Salvia medicinal plants 
(Fam. Lamiacae), a crude ethanolic extract from the 
aerial part of the plant Salvia cinnabarina 
demonstrated in vitro antispasmodic activity. This led 
to the isolation of a new diterpenoid of the pimarane 
skeleton, the compound 3,4-secoisopimar-4(18),7,15-
triene-3-oic acid (CMP1) [1], the complete relative 
stereochemistry of which was determined by an X-
ray diffraction analysis of a derivative [2] (Figure 1). 
Further studies have shown that CMP1 reduces 
intestinal motility in vivo [3], the urinary bladder 
contractility in vitro both with a mechanism 
involving calcium channel [4] and possess a weak 
hypotensive activity [5]. Diterpenoids are widely 
distributed throughout plant species, including    
some of the genus Salvia [6] displaying a spectrum  
of biological activities including those on the CNS 
[7]. Salvinorin A (Salvia divinorum), miltirone, 
tanshinones II A and II B, carnosol and carnosic   
acid (Salvia officinalis) are examples of isolated 
diterpenes with hallucinogenic, neuroprotective, 
sedative and hypnotic properties (for review see  [7]). 
This study investigates CMP1, for its CNS activity in 
 
 
Figure 1: CMP1, chemical structure. 
 
the hope that, as with other Salvia species, it may 
generate potential leads for novel CNS drugs. 
 
Our study shows that CMP1 (10 mg/kg ip.) has a 
potential  anxiolytic effect evaluated either as the 
time spent in, or as the number of entries to, the open 
arms of the plus maze. Both CMP1 and diazepam    
(2 mg/kg) were able to increase both the time spent 
and the number of entries into the open arms. 
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Figure 2: CMP1 effects in the plus maze test TOA, time spent in the open 
arms; NEOA, numbers of entry in the open arms. Animals were treated 
ip. 10 min before the test with CMP1 (1 and 10 mg/ kg) or 30 min before 
the test with diazepam (D, 1 and 2 mg/kg). Data are shown as percentage 
of the vehicle-induced effects (CMP1 vehicle: TOA, 22.4 ± 8.5 sec; 
NEOA, 3.1 ± 1.1; D vehicle: TOA, 21.1 ± 6.9 sec; NEOA, 2.9 ± 0.6).  
* p<0.05 vs vehicle-treated animals; § p<0.05 vs CMP1 (10). N = 12-15.  
 
Diazepam administered at the dose of 1 mg/kg was 
able to increase the number of entries into the open 
arms only, while CMP1 at the lowest dose (1 mg/kg) 
had no effect (Figure 2). Conversely, CMP1 does not 
display depressant activity, as it was ineffective in the 
swimming test (data not shown).  
 
Furthermore, our findings demonstrate sedative 
properties for CMP1 as its ability to potentiate 
sleeping time of a pentobarbital injection, as 
diazepam. Indeed, CMP1 (10 mg/kg) significantly 
increased the sleeping time induced by pentobarbital 
(218.8 ± 25.5%, t-test: t18 = 3.968, p < 0.001,            
N = 10). Similarly, treatment with diazepam             
(2 mg/kg) significantly increased the sleeping time 
induced by pentobarbital (164.4 ± 20.9%, t-test:       
t26 = 3.968, p < 0.01, N = 15). The increase in 
sleeping time observed after CMP1 or diazepam 
administration were in the same order of magnitude 
and were independent of the dosage; for simplicity 
we report only the results obtained after highest dose 
of administration. Whether this effect of CMP1 on 
pentobarbital induced sleeping time is due to a 
pharmacodynamic or a pharmacokinetic interaction 
needs further investigation.  
 
It is well known that a diazepam-induced sedative 
effect is paralleled by reduction in the spontaneous 
motor activity representing a possible limitation       
to its use [8]. This work showed CMP1 to have        
an anxiolytic effect without modifying total 
spontaneous motor activity and this may represent     
a therapeutically useful feature. Indeed, CMP1        
(10 mg/kg ip.) did not change the spontaneous motor 
 
Figure 3: CMP1 effects on total locomotor activity.Animals were treated 
with CMP1 (10 and 100 mg/kg), diazepam (D, 2 mg/kg) i.p or vehicle 
(V) immediately before the test. * p<0.05 vs vehicle-treated animals. N = 
6-8. 
 
activity of mice; while a dose of 100 mg/kg 
significantly reduced spontaneous motor activity, in 
contrast to Diazepam (2 mg/kg) which reduced 
spontaneous motor activity (Figure 3). 
 
In conclusion, our main finding is that CMP1, the 
major diterpenoid constituent of Salvia cinnabarina, 
has anxiolytic activity with fewer side effects in 
comparison to diazepam. Our findings further help 
delineate the pharmacological profile of diterpenoids 
and suggest that CMP1 could represent a lead 
compound for the development a new class of 
anxiolytics. 
 
Experimental 
 
Animals: Male CD-1 mice (Charles River, Italy) 
weighing 25–30 g were used for all experiments on 
CNS. Mice were housed in colony cages (7 mice in 
each cage) for at least 1 week before experimental 
sessions with the following conditions: exposed to 
normal light (from 7.00 a.m. to 7.00 p.m.); 
temperature 22 ± 1°C; relative humidity 60 ± 10%; 
and food and water available ad libitum. All 
experiments complied with the Italian D.L. N° 116 of 
1992 and associated guidelines in the European 
Communities Council Directive of 24 November 
1986 (86/609/ECC).  
 
Drugs and treatment procedure: Extraction of 
CMP1 from leaf surface constituents of fresh aerial 
parts of Salvia cinnabarina was performed as 
previously described [1] to a HPLC purity of 96%. 
The sodium salt (prepared by reaction with an 
equivalent quantity of NaOH in MeOH solution and 
evaporation to dryness) was dissolved (5 mg) in 
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distilled water. On each test day, an aliquot of drug 
solution was diluted with phosphate buffered saline 
(PBS) and then ip. injected in a volume of 35 mL/kg. 
Diazepam solutions were prepared in distilled water 
added with Tween 80 (2 drops every 10 mL), 
dispersed by ultrasound and given ip. in a volume of 
10 mL/kg. Drug dosage and time-courses were 
chosen on the basis of results obtained in preliminary 
experiments. 
 
Elevated plus-maze test: This test has been widely 
validated to measure anxiety in rodents [9,10]. The 
apparatus, constructed from black Plexiglas, 
consisted of two open arms (50 cm × 10 cm x 40 cm 
each), and two enclosed arms (50 cm × 10 cm × 40 
cm each) and a central platform (10 cm × 10 cm), 
arranged so that the two arms of a type were just 
opposite to the two arms of the other type. The maze 
was elevated 60 cm above the floor. Ten minutes 
after ip. treatment with CMP1 (1 and 10 mg/kg)       
or thirty minutes after ip. treatment with diazepam    
(1 and 2 mg/kg), or with the respective vehicle, each 
animal was placed at the centre of the maze, facing 
one of the closed arms. During 10 min period test, the 
number of open arms entries and the time (sec) spent 
in there was recorded. Animal behavior was 
monitored by using a video camera located above the 
maze.  
 
Pentobarbital-sleeping time: This test was performed 
according to Mora et al. [11]. Ten minutes after ip. 
treatment with CMP1 (10 mg/kg) or thirty minutes 
after ip. treatment with diazepam (1 and 2 mg/kg) or 
vehicles, each animal was ip. injected with 
pentobarbital (50 mg/kg). The time required to the 
mouse to lay on its back was recorded as the sleep 
latency. Sleeping time was taken as the period 
between the loss of the righting reflex and its return. 
Experiments were carried out in a quiet room in 
which temperature was maintained at 22 ± 2°C.  
 
Forced swimming test: The test was performed as 
described by Lucki [12] and Porsolt et al. [13]. 
Briefly, the apparatus consisted of a transparent 
plexiglas cylinder (50 cm × 20 cm diameter) filled  
up to 30 cm with water at room temperature. CMP1 
(1 and 10 mg/kg) or vehicle were administered        
10 min prior to the test. During 10 min test, floating, 
i.e. when mice made no further attempts to escape 
except the movements necessary to keep its head 
above the water, was recorded by a trained observer. 
Reduction in floating was considered an 
antidepressant-like action [14]. 
 
Spontaneous motor activity: Locomotor activity was 
recorded with an infrared photocell activity monitor 
(Ugo Basile, Italy), provided with one array of 15 
infrared photocells spaced 2.5 cm apart. Total 
spontaneous motor activity was monitored during 30 
min by evaluating all interruptions of photo beams, as 
described in literature [15]. All measurements were 
performed between 10:00 am and 1:00 pm. Animals 
were treated with CMP1 (10 and 100 mg/kg ip.), 
diazepam (1 and 2 mg/kg ip.) or the vehicles 
immediately before the test starting. 
 
Data analysis and statistics: All data are expressed 
as mean ± ES and analyzed using one-way analysis 
of variance (ANOVA) followed by Bonferroni’s test 
for multiple comparisons or by t-test when the 
comparison was between two means. A value of 
p<0.05 was considered statistically significant. 
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